- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer’s Disease ; volume:38 ; number:1 ; day:13 ; month:11 ; year:2023 ; pages:5-22 ; date:1.2024
BioDrugs ; 38, Heft 1 (13.11.2023), 5-22, 1.2024
- Urheber
-
Cummings, Jeffrey
Osse, Amanda M. Leisgang
Cammann, Davis
Powell, Jayde
Chen, Jingchun
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s40259-023-00633-2
- URN
-
urn:nbn:de:101:1-2024032721020156216725
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:51 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Cummings, Jeffrey
- Osse, Amanda M. Leisgang
- Cammann, Davis
- Powell, Jayde
- Chen, Jingchun
- SpringerLink (Online service)
Ähnliche Objekte (12)
Anti-Amyloid Monoclonal Antibodies are Transformative Treatments that Redefine Alzheimer's Disease Therapeutics
Amyloid-Lowering Monoclonal Antibodies for the Treatment of Early Alzheimer’s Disease
Editorial: A Time of Transition of Alzheimer's Disease in the Advent of Anti-Amyloid Monoclonal Antibodies
Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer’s disease
News & views: anti-amyloid antibodies and novel emerging approaches to Alzheimer’s disease in 2023
A Framework for the Administration of Anti-amyloid Monoclonal Antibody Treatments in Early-Stage Alzheimer’s Disease
The FDA-approved anti-amyloid-β monoclonal antibodies for the treatment of Alzheimer’s disease: a systematic review and meta-analysis of randomized controlled trials
Critical assessment of anti-amyloid-β monoclonal antibodies effects in Alzheimer’s disease: a systematic review and meta-analysis highlighting target engagement and clinical meaningfulness
Development and characterization of novel anti-acetylated tau monoclonal antibodies to probe pathogenic tau species in Alzheimer’s disease
Anti-Amyloid Immunotherapies for Alzheimer’s Disease: A 2023 Clinical Update
Anti-Amyloid Therapies for Alzheimer’s Disease: An Alzheimer Europe Position Paper and Call to Action
Passive Anti-amyloid Beta Monoclonal Antibodies: Lessons Learned over Past 20 Years
Anti-Amyloid Monoclonal Antibodies are Transformative Treatments that Redefine Alzheimer's Disease Therapeutics
Amyloid-Lowering Monoclonal Antibodies for the Treatment of Early Alzheimer’s Disease
Editorial: A Time of Transition of Alzheimer's Disease in the Advent of Anti-Amyloid Monoclonal Antibodies
Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer’s disease
News & views: anti-amyloid antibodies and novel emerging approaches to Alzheimer’s disease in 2023
A Framework for the Administration of Anti-amyloid Monoclonal Antibody Treatments in Early-Stage Alzheimer’s Disease
The FDA-approved anti-amyloid-β monoclonal antibodies for the treatment of Alzheimer’s disease: a systematic review and meta-analysis of randomized controlled trials
Critical assessment of anti-amyloid-β monoclonal antibodies effects in Alzheimer’s disease: a systematic review and meta-analysis highlighting target engagement and clinical meaningfulness
Development and characterization of novel anti-acetylated tau monoclonal antibodies to probe pathogenic tau species in Alzheimer’s disease
Anti-Amyloid Immunotherapies for Alzheimer’s Disease: A 2023 Clinical Update
Anti-Amyloid Therapies for Alzheimer’s Disease: An Alzheimer Europe Position Paper and Call to Action
Passive Anti-amyloid Beta Monoclonal Antibodies: Lessons Learned over Past 20 Years
Anti-Amyloid Monoclonal Antibodies are Transformative Treatments that Redefine Alzheimer's Disease Therapeutics
Amyloid-Lowering Monoclonal Antibodies for the Treatment of Early Alzheimer’s Disease
Editorial: A Time of Transition of Alzheimer's Disease in the Advent of Anti-Amyloid Monoclonal Antibodies
Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer’s disease
News & views: anti-amyloid antibodies and novel emerging approaches to Alzheimer’s disease in 2023
A Framework for the Administration of Anti-amyloid Monoclonal Antibody Treatments in Early-Stage Alzheimer’s Disease
The FDA-approved anti-amyloid-β monoclonal antibodies for the treatment of Alzheimer’s disease: a systematic review and meta-analysis of randomized controlled trials
Critical assessment of anti-amyloid-β monoclonal antibodies effects in Alzheimer’s disease: a systematic review and meta-analysis highlighting target engagement and clinical meaningfulness
Development and characterization of novel anti-acetylated tau monoclonal antibodies to probe pathogenic tau species in Alzheimer’s disease
Anti-Amyloid Immunotherapies for Alzheimer’s Disease: A 2023 Clinical Update
Anti-Amyloid Therapies for Alzheimer’s Disease: An Alzheimer Europe Position Paper and Call to Action